LIM
Lagoda Investment Management Portfolio holdings
AUM
$177M
This Quarter Return
+17.82%
1 Year Return
+46.81%
3 Year Return
+194.86%
5 Year Return
+427.13%
10 Year Return
+1,154.94%
AUM
$333M
AUM Growth
+$333M
(+24%)
Cap. Flow
+$28.3M
Cap. Flow
% of AUM
8.51%
Top 10 Holdings %
Top 10 Hldgs %
70.78%
Holding
29
New
1
Increased
14
Reduced
8
Closed
–
Top Buys
| 1 |
MON
Monsanto Co
MON
|
$10.1M |
| 2 |
VolitionRX
VNRX
|
$6.92M |
| 3 |
Ubiquiti
UI
|
$6.65M |
| 4 |
TTOO
T2 Biosystems, Inc
TTOO
|
$3.34M |
| 5 |
Digimarc
DMRC
|
$1.9M |
Top Sells
| 1 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$2.37M |
| 2 |
Novo Nordisk
NVO
|
$1.27M |
| 3 |
Berkshire Hathaway Class A
BRK.A
|
$432K |
| 4 |
ESGR
Enstar Group
ESGR
|
$392K |
| 5 |
Mastercard
MA
|
$350K |
Sector Composition
| 1 | Healthcare | 48.15% |
| 2 | Technology | 20.9% |
| 3 | Communication Services | 12.14% |
| 4 | Financials | 9.29% |
| 5 | Materials | 5.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AbbVie
ABBV
$372B
| $31K | 0.01% |
491
| – | – |
|
27
Abbott
ABT
$231B
| $27K | 0.01% |
640
| – | – |
|
28
Phillips 66
PSX
$54B
| $16K | ﹤0.01% |
197
| – | – |
|
29
GSK
GSK
$79.9B
| $8K | ﹤0.01% |
174
| – | – |
|